Applied Optoelectronics (AAOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Fabrinet outshines Applied Optoelectronics with steady telecom and data center growth, while rising costs weigh on AAOI's near-term outlook.
Applied Optoelectronics, Inc. is well positioned to capitalize on the AI infrastructure boom, initiating coverage with a Buy rating. AAOI's aggressive capacity ramp, automation advances, and new Texas facility support ambitions to capture a rapidly expanding $60B TAM by 2030. 2026 revenue is guided north of $1B (119%+ growth), with adjusted operating income over $120M, demonstrating accelerating business momentum for AAOI.
Applied Optoelectronics' CATV revenues surge as 1.8 GHz amplifier demand rises, with Q1 outlook pointing to strong sequential growth.
AAOI stock has surged 722% in a year, but its path to $1B revenue and non-GAAP profitability in 2026 hinges on ramps, product mix and hyperscaler order timing.
Photonics stocks are set to profit from the massive AI-buildout regardless of which AI model or hyperscaler eventually wins the software war.
Applied Optoelectronics stock soars 129% in a month on strong results and 800G demand, but rising costs and tariff risks warrant caution.
Applied Optoelectronics is ramping 800G transceivers as hyperscale demand surges, positioning the data center segment for strong growth.
Are you feeling the whipsaw? Shares of Applied Optoelectronics (AAOI) and Lumentum (LITE) both surgied roughly 15% in Monday's session, with AAOI trading at $110.62 and LITE at $640.69.
Applied Optoelectronics is riding an AI-driven optics cycle as 800G ramps in 2026, 1.6T follows and new Texas capacity aims to boost supply.
AAOI targets $1B+ revenues by 2026, as AI-driven 800G demand ramps, but capacity, supply chain and staffing will dictate how hyperscaler orders convert to sales.
While February tested investor patience with its choppy action and internal weakness, the data entering March tells a vastly different story.